Y-mabs appoints experienced commercial leader as head of danyelza business unit

New york, jan. 10, 2025 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of doug gentilcore as senior vice president, head of danyelza business unit.
YMAB Ratings Summary
YMAB Quant Ranking